Growing Academic-Industry Research Partnerships
The mission of Biomedical Sciences Industry Partnership Office (BMSIPO) is to catalyse academic-industry research and clinical partnerships across Singapore’s ecosystem, helping businesses grow and deliver innovative healthcare solutions.
What Sets Us Apart
BMSIPO specialises in understanding our industry partners’ research and development interests, bringing together groups with the right capabilities, and crafting win-win collaboration models.
Since our inception as a publicly-funded national platform in 2010, we have been forging strategic alliances that foster research and development (R&D) and clinical partnerships between industry partners and public research and healthcare institutions in Singapore.
Tailored Solutions For All
Whether you’re a nimble Singapore startup or multi-national corporation with global networks, BMSIPO is your strategic ally.
We take pride in developing partnerships that encompass the entire spectrum of R&D – from discovery research to technology development, pre-clinical to clinical development, translational clinical studies, and even manufacturing and process technology development. BMSIPO can be your strategic partner to help advance your R&D roadmap like never before.
Learn More
What Our Partners Say
BMSIPO has been a tremendous support to Singapore Translational Cancer Consortium’s mission. Their networks to industry partners both international and in Singapore, and experience in structuring collaboration agreements has helped STCC accelerate our efforts.
Professor Chng Wee Joo
Executive Director, STCC
BMSIPO has been an invaluable partner to CPR and their unwavering support has been instrumental in accelerating collaborative research with the local scientific environment, especially for the dengue and COVID-19 projects with A*STAR. We’re confident that our continued interactions with BMSIPO will yield greater future successes.
Dr Hideaki Shimada
CEO of Chugai Pharmabody Research (CPR), a wholly-owned subsidiary of Chugai Pharmaceutical
TRUST is appreciative of BMSIPO’s support to the research community. As the national data sharing and analytics platform for health-biomedical research, we value the partnership with BMSIPO to enable cutting-edge data driven innovations and partnerships for the benefit of our society.
Mingshi Koh
Director, TRUST Office
PRECISE has benefited immensely from BMSIPO’s collective knowledge and experience in forging multi-institutional research projects and long-term strategic partnerships with the pharmaceutical and biomedical industry. We look forward to continuing our fruitful collaboration with BMSIPO to drive innovation and shape the future of healthcare.
Professor Patrick Tan
Executive Director, PRECISE
Updates
FY2026 HHP I&E Workplan Sharing Workshop
HHP I&E community representatives came together to share RIE2030 Therapeutics and MedTech strategies, as well as institutional workplans, thereby strengthening collaboration across the ecosystem.
Learn More
Scaling Therapeutics Companies for Global Impact
BMSIPO brought together dynamic industry leaders for a panel on scaling therapeutic companies for global impact. The discussion offered valuable perspectives on the journey from building startups to scaling globally.
Learn More
From Bench to Business: Building MedTech Ventures That Matter
BMSIPO and HealthTEC.SG brought together researchers, clinicians, and innovators for a candid panel on what it truly takes to translate biomedical innovation into MedTech ventures with real clinical and commercial impact.
Learn More
A shared data foundation for the future of precision medicine
A global pharmaceutical consortium is partnering Singapore’s PRECISE programme to harness one of Asia’s most diverse population health datasets and accelerate discoveries in precision medicine.
Learn More
Building Science That Endures
A five-decade partnership shows how Singapore’s biomedical ecosystem enables global science to become regionally relevant, clinically grounded and built to last.
Learn More
Ushering in the Next Generation of Cell Therapies in Singapore
Elpis Biopharmaceuticals and Singapore General Hospital are joining forces to develop effective and accessible next generation cancer therapies.
Learn More